12. November 2024 – Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today that it has raised USD 181.4 million in Series D financing, supported by a syndicate of top-tier biotech investors. The financing will support Alentis to develop a deep pipeline of CLDN1 targeted medicines for solid tumors.

The funding round was led by OrbiMed with co-leads Novo Holdings and Jeito Capital. New investors Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Heartland Healthcare Capital and Avego Bioscience Capital participated in the round. Significant backing was also received from existing investor RA Capital Management, along with support from Morningside Venture Investments, BB Pureos, Bpifrance through its InnoBio 2 fund, as well as other early institutional investors, all of whom have been instrumental to Alentis’ development path.

Walder Wyss advised Alentis in this financing round. The Walder Wyss team was led by Iliana Djagova (Counsel, Corporate/M&A) and included Carmen Spichiger (Senior Associate, Corporate/M&A), Alexander Gutmans (Partner, Corporate/M&A), Alex Nikitine (Partner, Corporate/M&A), Karina Tschon (Managing Associate, Corporate/M&A), Thomas Müller (Partner, Finance), Manu Ferro (Senior Associate, Finance), Katja Schott-Morgenroth (Partner, Corporate/M&A) and Jan Sutter (Junior Lawyer, Corporate/M&A).